Researchers evaluated the effectiveness of the updated mRNA-1273 KP.2 vaccine against COVID-19 hospitalizations in US adults during the 2024-2025 season.
RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.
A multi-disciplinary research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute, and ...
A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.
Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...
An analysis of 76 million people found that those who had been ill with Covid were at greater risk of developing one cancer ...
Morning Overview on MSN
Scientists are about to unleash the 1st ever universal vaccine
Stanford Medicine researchers reported this week that an intranasal vaccine formula protected mice against a striking range of respiratory threats, from SARS-CoV-2 to bacterial infections, in what ...
Read more about Future pandemics may be fought faster with mRNA and advanced vaccine platforms on Devdiscourse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results